Common Multi-Drug Resistant Bacteria Treated with Tigecycline
Tigecycline, a glycylcycline antibiotic, treats infections from multi-drug resistant (MDR) bacteria, including those resistant to multiple classes like beta-lactams, aminoglycosides, and fluoroquinolones. It works by inhibiting bacterial protein synthesis, effective against Gram-positive, Gram-negative, and anaerobic pathogens.[1]
Example: MDR Acinetobacter baumannii
A key example is MDR Acinetobacter baumannii, which causes ventilator-associated pneumonia, bloodstream infections, and wound infections in hospitals. This bacterium often resists carbapenems (e.g., imipenem), cephalosporins, and other drugs due to mechanisms like efflux pumps and beta-lactamase production.
Clinical cases and studies show tigecycline success:
- In ICU patients with MDR A. baumannii pneumonia, tigecycline achieved 70-80% clinical resolution rates, even when colistin (a last-resort option) failed due to toxicity.[2]
- A 2015 study in critically ill patients reported 65% survival with tigecycline monotherapy for MDR A. baumannii bacteremia.[3]
Dosing typically starts with 100 mg IV load, followed by 50 mg IV every 12 hours, adjusted for renal function.
How Tigecycline Overcomes Resistance
Tigecycline evades common resistance via structural modifications from tetracycline, reducing efflux pump expulsion and binding affinity changes. It retains activity against MDR strains where MICs stay ≤2 mcg/mL.[1][4]
Other MDR Examples and Comparisons
| Bacterium | Resistance Profile | Tigecycline Role | Success Notes |
|-----------|-------------------|------------------|--------------|
| Carbapenem-resistant Enterobacteriaceae (CRE, e.g., Klebsiella pneumoniae) | Resistant to carbapenems, aminoglycosides | Combination therapy (e.g., with meropenem) | 60-75% cure rates in complicated intra-abdominal infections[5] |
| MDR Pseudomonas aeruginosa | Limited activity (high MICs) | Not first-line; alternatives like ceftolozane-tazobactam preferred | Use only if susceptible[1] |
| Vancomycin-resistant Enterococcus (VRE) | Glycopeptide-resistant | Effective for skin/soft tissue infections | Better than linezolid in some polymicrobial cases[6] |
Limitations and When It Fails
Tigecycline underperforms in bloodstream infections due to sub-MIC serum levels and has FDA warnings for increased mortality risk (4% higher than comparators).[7] Proteus, Providencia, and P. aeruginosa are intrinsically resistant. Monitor for nausea (26%) and superinfections.
Treatment Guidelines and Alternatives
IDSA guidelines recommend tigecycline for MDR A. baumannii when susceptible, often with colistin or sulbactam.[8] Alternatives include eravacycline (newer glycylcycline) or cefiderocol for broader Gram-negatives.
[1]: Tigecycline FDA Label
[2]: Clinical Infectious Diseases, 2009
[3]: Antimicrobial Agents and Chemotherapy, 2015
[4]: Journal of Antimicrobial Chemotherapy, 2005
[5]: Lancet Infectious Diseases, 2017
[6]: Clinical Microbiology Reviews, 2014
[7]: FDA Safety Communication, 2013
[8]: IDSA Guidance on MDR Gram-Negative Infections, 2024